BR112012033435A2 - solução oftálmica e frasco de dose única ou multi-dose feito de pebd sem aditivos. - Google Patents

solução oftálmica e frasco de dose única ou multi-dose feito de pebd sem aditivos.

Info

Publication number
BR112012033435A2
BR112012033435A2 BR112012033435A BR112012033435A BR112012033435A2 BR 112012033435 A2 BR112012033435 A2 BR 112012033435A2 BR 112012033435 A BR112012033435 A BR 112012033435A BR 112012033435 A BR112012033435 A BR 112012033435A BR 112012033435 A2 BR112012033435 A2 BR 112012033435A2
Authority
BR
Brazil
Prior art keywords
ophthalmic solution
pebd
additives
dose vial
vial made
Prior art date
Application number
BR112012033435A
Other languages
English (en)
Other versions
BR112012033435B1 (pt
Inventor
Fabrice Mercier
Original Assignee
Thea Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43064334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012033435(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thea Lab filed Critical Thea Lab
Publication of BR112012033435A2 publication Critical patent/BR112012033435A2/pt
Publication of BR112012033435B1 publication Critical patent/BR112012033435B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

solução ofálmica e frasco de dose única ou multi-dose feito de pebd sem aditivos. esta invenção diz respeito a uma solução oftálmica incluindo; - pelo menos uma prostaglandina; um agente solubilizante; - um agente gelificante do tipo carbômero; - um agente inibidor de polimerização de carbômero; - um agente cogelificante/cossolubilizante.
BR112012033435-2A 2010-06-29 2011-06-28 Solução oftálmica, seu uso e frasco de dose única ou multi-dose feito de polietileno de baixa densidade sem aditivos BR112012033435B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35969910P 2010-06-29 2010-06-29
US61/359,699 2010-06-29
FR1055236 2010-06-29
FR1055236A FR2961694B1 (fr) 2010-06-29 2010-06-29 Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
PCT/EP2011/060848 WO2012001009A1 (fr) 2010-06-29 2011-06-28 Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur

Publications (2)

Publication Number Publication Date
BR112012033435A2 true BR112012033435A2 (pt) 2016-11-22
BR112012033435B1 BR112012033435B1 (pt) 2022-03-29

Family

ID=43064334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033435-2A BR112012033435B1 (pt) 2010-06-29 2011-06-28 Solução oftálmica, seu uso e frasco de dose única ou multi-dose feito de polietileno de baixa densidade sem aditivos

Country Status (27)

Country Link
US (2) US20110319487A1 (pt)
EP (1) EP2588078B1 (pt)
JP (2) JP5657789B2 (pt)
KR (1) KR101809713B1 (pt)
CN (2) CN102958509B (pt)
AU (1) AU2011273549B2 (pt)
BR (1) BR112012033435B1 (pt)
CA (1) CA2802816C (pt)
CL (1) CL2012003684A1 (pt)
CO (1) CO6660508A2 (pt)
DK (1) DK2588078T3 (pt)
EA (1) EA025026B1 (pt)
ES (1) ES2486793T3 (pt)
FR (1) FR2961694B1 (pt)
HK (2) HK1178446A1 (pt)
HR (1) HRP20140631T1 (pt)
MA (1) MA34324B1 (pt)
MX (1) MX2012014503A (pt)
PL (1) PL2588078T3 (pt)
PT (1) PT2588078E (pt)
RS (1) RS53417B (pt)
SG (1) SG186361A1 (pt)
SI (1) SI2588078T1 (pt)
SM (1) SMT201400098B (pt)
TN (1) TN2012000588A1 (pt)
UA (1) UA107718C2 (pt)
WO (1) WO2012001009A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672624T3 (es) 2009-05-01 2018-06-15 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedades
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
WO2014134689A1 (en) * 2013-03-08 2014-09-12 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
WO2015055301A1 (en) 2013-10-15 2015-04-23 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
GR1008330B (el) * 2013-10-17 2014-10-20 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση εχoν βελτιωμενες φυσικες ιδιοτητες και ογκο σταγονας
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
PL3103439T3 (pl) * 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
IT201600103956A1 (it) * 2016-10-17 2018-04-17 Omikron Italia S R L Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate
NZ756626A (en) 2017-03-14 2022-10-28 Polyactiva Pty Ltd Drug-polymer conjugate
JP6931493B2 (ja) 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
AU2019300203A1 (en) * 2018-07-12 2021-03-04 Nicox S.A. Ophthalmic compositions containing a nitric oxide releasing prostamide
CA3145888A1 (en) * 2018-07-31 2020-02-06 Isilay KAVADARLI Ophthalmic formulations and uses thereof
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN110711175A (zh) * 2019-11-12 2020-01-21 南京华盖制药有限公司 一种他氟前列素滴眼剂及其制备方法
US11857538B2 (en) * 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
US11857539B2 (en) 2022-02-09 2024-01-02 Somerset Therapeutics, Llc Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10021A (en) * 1853-09-13 Screw-eastemtito- for boots and shoes
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
CN1138542C (zh) * 1998-04-02 2004-02-18 诺瓦提斯公司 通过特定应用的抗氧化剂稳定药物组合物的方法
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
UA100393C2 (ru) * 2007-10-16 2012-12-25 Сан Фарма Адвансед Ресьорч Компані Лімітед Новые офтальмологические композиции
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur

Also Published As

Publication number Publication date
EP2588078B1 (fr) 2014-05-14
HRP20140631T1 (hr) 2014-09-26
UA107718C2 (en) 2015-02-10
FR2961694B1 (fr) 2013-01-25
SG186361A1 (en) 2013-01-30
HK1178446A1 (en) 2013-09-13
JP5657789B2 (ja) 2015-01-21
CO6660508A2 (es) 2013-04-30
SI2588078T1 (sl) 2014-09-30
PL2588078T3 (pl) 2014-09-30
EA201291307A1 (ru) 2013-05-30
HK1201464A1 (en) 2015-09-04
CA2802816C (fr) 2015-05-12
SMT201400098B (it) 2014-09-08
US20120322871A1 (en) 2012-12-20
CN104274396B (zh) 2017-07-04
CA2802816A1 (fr) 2012-01-05
DK2588078T3 (da) 2014-08-18
EP2588078A1 (fr) 2013-05-08
FR2961694A1 (fr) 2011-12-30
RS53417B (en) 2014-12-31
CL2012003684A1 (es) 2013-03-08
WO2012001009A1 (fr) 2012-01-05
CN104274396A (zh) 2015-01-14
CN102958509A (zh) 2013-03-06
EA025026B1 (ru) 2016-11-30
MA34324B1 (fr) 2013-06-01
AU2011273549A1 (en) 2013-01-10
JP5877885B2 (ja) 2016-03-08
US20110319487A1 (en) 2011-12-29
BR112012033435B1 (pt) 2022-03-29
ES2486793T3 (es) 2014-08-19
KR101809713B1 (ko) 2017-12-15
MX2012014503A (es) 2013-01-29
KR20130112728A (ko) 2013-10-14
JP2015038099A (ja) 2015-02-26
JP2013532159A (ja) 2013-08-15
PT2588078E (pt) 2014-07-16
AU2011273549B2 (en) 2013-06-27
TN2012000588A1 (fr) 2014-04-01
CN102958509B (zh) 2015-01-21
US8637054B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
BR112012033435A2 (pt) solução oftálmica e frasco de dose única ou multi-dose feito de pebd sem aditivos.
CY1119684T1 (el) Αντι-ιικες ενωσεις
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112017000808A2 (pt) espirociclo-heptanos como inibidores de rock
CR20130045A (es) Compuestos terapéuticos
EA201590586A1 (ru) Терапевтические наночастицы, включающие терапевтический агент, способы их получения и применения
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
GEP20166438B (en) Imidazopyrrolidinone compounds
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
PE20150887A1 (es) Compuestos de benceno sustituidos
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
UY33497A (es) Derivados de espiro-piperidina como moduladores s1p
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
MX359884B (es) Derivado del acido hialuronico con aminoacido y grupo esterilo introducido en este.
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.